PTC Therapeutics (NASDAQ:PTCT) Insider Sells $80,588.80 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 1,024 shares of PTC Therapeutics stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $78.70, for a total transaction of $80,588.80. Following the sale, the insider owned 80,141 shares in the company, valued at approximately $6,307,096.70. The trade was a 1.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total transaction of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.50, for a total transaction of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.06, for a total value of $240,342.12.

PTC Therapeutics Stock Performance

NASDAQ:PTCT traded up $0.06 during trading hours on Monday, reaching $77.59. The stock had a trading volume of 2,631,928 shares, compared to its average volume of 1,795,906. The stock has a market capitalization of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The company has a 50 day moving average price of $76.61 and a two-hundred day moving average price of $62.91.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same period last year, the firm posted ($1.39) earnings per share. PTC Therapeutics’s revenue for the quarter was up 7.2% compared to the same quarter last year. Equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PTCT. Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Barclays lifted their target price on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Wells Fargo & Company boosted their target price on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, The Goldman Sachs Group raised their price target on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $77.27.

Institutional Trading of PTC Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC lifted its position in shares of PTC Therapeutics by 587.5% during the fourth quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock worth $67,943,000 after purchasing an additional 764,364 shares during the last quarter. Diversified Trust Co. increased its stake in PTC Therapeutics by 4.9% in the 4th quarter. Diversified Trust Co. now owns 17,394 shares of the biopharmaceutical company’s stock worth $1,321,000 after buying an additional 817 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in PTC Therapeutics by 9.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 806 shares in the last quarter. GAMMA Investing LLC boosted its position in PTC Therapeutics by 160.0% in the 4th quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 893 shares during the period. Finally, IFP Advisors Inc boosted its position in PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 310 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.